Iron Overload Promotes Erythroid Apoptosis Through Regulating HIF-1a/ROS Signaling Pathway in Patients with Myelodysplastic Syndrome
Overview
Authors
Affiliations
Erythroid apoptosis increases significantly in myelodysplastic syndrome (MDS) patients with iron overload, but the underlying mechanism is not fully clear. In this study, we aim to explore the effect of HIF-1a/ROS on erythroid apoptosis in MDS patients with iron overload. We found that iron overload injured cellular functions through up-regulating ROS levels in MDS/AML cells, including inhibited cell viability, increased cell apoptosis and blocked cell cycle at G0/G1 phase. Interestingly, overexpression of hypoxia inducible factor-1a (HIF-1a), which was under-expressed in iron overload models, reduced ROS levels and attenuated cell damage caused by iron overload in MDS/AML cells. And gene knockdown of HIF-1a got the similar results as iron overload in MDS/AML cells. Furthermore, iron overload caused high erythroid apoptosis was closely related with ROS in MDS patients. Importantly, the HIF-1a protein levels of erythrocytes elevated obviously after incubation with desferrioxamine (DFO) from MDS patients with iron overload, accompanied by ROS levels inhibited and erythroid apoptosis reduced. Taken together, our findings determine that the HIF-1a/ROS signaling pathway plays a key role in promoting erythroid apoptosis in MDS patients with iron overload.
Cardiac injury caused by iron overload in thalassemia.
Fu C, Yang X Front Pediatr. 2025; 13:1514722.
PMID: 39931654 PMC: 11808023. DOI: 10.3389/fped.2025.1514722.
Biological Iron Removal and Recovery from Water and Wastewater.
Kaksonen A, Janneck E Adv Biochem Eng Biotechnol. 2024; 190:31-88.
PMID: 38951134 DOI: 10.1007/10_2024_255.
Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies.
Zhang H, Sun C, Sun Q, Li Y, Zhou C, Sun C Front Mol Biosci. 2023; 10:1275774.
PMID: 37818101 PMC: 10561097. DOI: 10.3389/fmolb.2023.1275774.
Ijabi R, Kaminsky Z, Roozehdar P, Ijabi J, Moradi-Sardareh H, Tehranian N Curr Med Chem. 2023; 31(34):5638-5656.
PMID: 37724672 DOI: 10.2174/0929867331666230915103147.
Zhang Y, Qian Y, Song L, Xiao C, Chang C Front Oncol. 2022; 12:1058482.
PMID: 36523997 PMC: 9746802. DOI: 10.3389/fonc.2022.1058482.